How Covid-19 has Changed the eCOA/ePRO Landscape

How Covid-19 has Changed the eCOA/ePRO Landscape
December 23, 2020 YPrime

During the height of COVID-19, the life science industry had to decide whether to suspend, modify, or cancel their existing clinical trials and had to reprioritize their 2020 pipelines, which of course had been years in the planning.

COVID-19 initially affected the electronic clinical outcome assessment (eCOA) and electronic patient reported outcome (ePRO) components for clinical trials that were ongoing when the pandemic began. However, sponsors who were already using eCOA in their clinical trials may have had an easier time of it, finding it was less of a lift to keep their eCOA data flowing.

In this webinar, Donna M. Mongiello talks about how COVID-19 changed the eCOA/ePRO landscape—the challenges experienced and changes implemented to continue seamless eCOA and ePRO data collection for these trials.

Watch the webinar to learn more about the growing importance of eCOA and ePRO.

WEBINAR

How Covid-19 has Changed the eCOA/ePRO Landscape

Donna M. Mongiello, RN, BSN Vice President, Strategic Solutions

RELATED CONTENT

Understanding Electronic Patient-Reported Outcomes (ePRO) in Clinical Development

Understanding Electronic Patient-Reported Outcomes (ePRO) in Clinical Development

eCOA Rescue and Rapid Deployment for a Phase 3 Respiratory Study

eCOA Rescue and Rapid Deployment for a Phase 3 Respiratory Study

Electronic Clinical Outcome Assessment (eCOA) For Clinical Studies

Electronic Clinical Outcome Assessment (eCOA) For Clinical Studies

LATEST CONTENT

How Modern Software Architecture is Revolutionizing IRT Solutions

How Modern Software Architecture is Revolutionizing IRT Solutions

eConsent for Clinical Trials

eConsent for Clinical Trials

Optimizing Strategies and Technologies for Decentralized and Hybrid Clinical Trials eBook

Optimizing Strategies and Technologies for Decentralized and Hybrid Clinical Trials eBook